[Retracted] The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies

Table 1

Immune blocking antibodies treatments and status of clinical trials.

Antibody	Target	Trial ID	Company	Cl. phase	Patients number	Treatment	Primary endpoint	Status	Results
Tremelimumab	CLTA-4	NCT01008358; Interventional; Nonrandomized	Medimmune, USA, Pfizer, USA	II	21	Monotherapy	Antitumor and antiviral effect	Completed	Disease control; rate of 76.4%; Median OS 8.2 month [95% CI: 4.64, 21.34]
Tremelimumab	CLTA-4	NCT01853618; Interventional; Nonrandomized	Medimmune, USA, Pfizer, USA	I	Recruiting	In combination; with RFA or TACE	Safety	Ongoing	Completion date: December 2015
Ipilimumab	CTLA-4	N/A	Bristol-Myers Squibb, USA	N/A	N/A	N/A	N/A	N/A	N/A
Nivolumab	PD-1	NCT01658878; Interventional; Nonrandomized	Bristol-Myers Squibb, USA	I	Recruiting; (target: 72)	Monotherapy	Safety/antitumor efficacy study	Ongoing	Completion date: May 2016
CT-011	PD-1	NCT00966251; Interventional; Nonrandomized	CureTech, Israel	I/II	2	Monotherapy	Safety	Terminated	Stopped due to; slow accrual
Lambrolizumab	PD-1	N/A	MK-3475, Merck, USA	N/A	N/A	N/A	N/A	N/A	N/A
AMP-224	PD-1	N/A	Amplimmune, USA	N/A	N/A	N/A	N/A	N/A	N/A
MEDI4376	PD-L1		MedImmune, USA, AstraZeneca, UK	I	Recruiting	Monotherapy	Safety/antitumor efficacy	Ongoing	N/A